HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional investor to advance its Phase I clinical trials for a promising new therapy targeting acute myeloid leukemia. The funds will support the development of their HEMO-CAR-T program, marking a significant step toward offering innovative treatment options for patients. Shares related to this investment are expected to commence trading on the London Stock Exchange by mid-November.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
